{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:16:00Z","timestamp":1761808560782,"version":"3.41.2"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>At present, androgen deprivation therapy (ADT) is still the standard regimen for patients with metastatic and locally advanced prostate cancer (PCa). The level of androgen receptor splice variant-7 (AR-V7) in men with castration-resistant prostate cancer (CRPC) has been reported to be elevated compared with that in patients diagnosed with hormone-sensitive prostate cancer (HSPC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>Herein, we performed a systematic review and cumulative analysis to evaluate whether the expression of AR-V7 was significantly higher in patients with CRPC than in HSPC patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The commonly used databases were searched to identify the potential studies reporting the level of AR-V7 in CRPC and HSPC patients. The association between CRPC and the positive expression of AR-V7 was pooled by using the relative risk (RR) with the corresponding 95% confidence intervals (CIs) under a random-effects model. For detecting the potential bias and the heterogeneity of the included studies, sensitivity analysis and subgroup analysis were performed. Publication bias was assessed Egger\u2019s and Begg\u2019s tests. This study was registered on PROSPERO (ID: CRD42022297014).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This cumulative analysis included 672 participants from seven clinical trials. The study group contained 354 CRPC patients, while the other group contained 318 HSPC patients. Pooled results from the seven eligible studies showed that the expression of positive AR-V7 was significantly higher in men with CRPC compared to those with HSPC (RR = 7.55, 95% CI: 4.61\u201312.35, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). In the sensitivity analysis, the combined RRs did not change substantially, ranging from 6.85 (95% CI: 4.16\u201311.27, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) to 9.84 (95% CI: 5.13\u201318.87, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). In the subgroup analysis, a stronger association was detected in RNA <jats:italic>in situ<\/jats:italic> hybridization (RISH) measurement in American patients, and those studies were published before 2011 (all <jats:italic>p<\/jats:italic> &amp;lt; 0.001). There was no significant publication bias identified in our study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Evidence from the seven eligible studies demonstrated that patients with CRPC had a significantly elevated positive expression of AR-V7. More investigations are still warranted to clarify the association between CRPC and AR-V7 testing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>, identifier CRD42022297014.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1053111","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T19:56:58Z","timestamp":1676404618000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The positive relationship between androgen receptor splice variant-7 expression and the risk of castration-resistant prostate cancer: A cumulative analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Shankun","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maolei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.07.018","article-title":"Efficacy and safety of darolutamide in patients with nonmetastatic castration-resistant prostate cancer stratified by prostate-specific antigen doubling time: Planned subgroup analysis of the phase 3 ARAMIS trial","author":"Bogemann","year":"2022","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2021.06.006","article-title":"Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance","volume":"518","author":"Jamroze","year":"2021","journal-title":"Cancer Lett"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0851","article-title":"Assessment of androgen receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancer","volume":"28","author":"Sowalsky","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202152764","article-title":"The androgen receptor depends on ligand-binding domain dimerization for transcriptional activation","volume":"22","author":"El","year":"2021","journal-title":"EMBO Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3390\/cells11050898","article-title":"Androgen receptor-mediated transcription in prostate cancer","volume":"11","author":"Ozturan","year":"2022","journal-title":"Cells"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.25600","article-title":"Association of gonadotropin-releasing hormone agonists for prostate cancer with cardiovascular disease risk and hypertension in men with diabetes","volume":"5","author":"Lin","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.05.030","article-title":"Patient-reported outcomes in men with metastatic castration-resistant prostate cancer harboring DNA damage response alterations treated with talazoparib: Results from TALAPRO-1","author":"Saad","year":"2022","journal-title":"Eur Urol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01737-1","article-title":"Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer","volume":"40","author":"Zhou","year":"2021","journal-title":"Oncogene"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0422","article-title":"Androgen receptor signaling in castration-resistant prostate cancer: A lesson in persistence","volume":"23","author":"Coutinho","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60172-9","article-title":"Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study","volume":"375","author":"Scher","year":"2010","journal-title":"Lancet"},{"key":"B13","article-title":"Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer","volume":"61","author":"Linja","year":"2001","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505253322101","article-title":"Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer","volume":"332","author":"Taplin","year":"1995","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M307649200","article-title":"Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer","volume":"279","author":"Gregory","year":"2004","journal-title":"J Biol Chem"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2006.08.021","article-title":"Regulation of androgen receptor activity by tyrosine phosphorylation","volume":"10","author":"Guo","year":"2006","journal-title":"Cancer Cell"},{"key":"B17","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3390\/genes13020378","article-title":"Epigenetic and epitranscriptomic control in prostate cancer","volume":"13","author":"Lopez","year":"2022","journal-title":"Genes (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.3390\/cancers13112563","article-title":"AR splicing variants and resistance to AR targeting agents","volume":"13","author":"Kanayama","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-02619-0","article-title":"Role of androgen receptor splice variants, their clinical relevance and treatment options","volume":"38","author":"Wach","year":"2020","journal-title":"World J Urol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1159\/000510124","article-title":"Molecular origin, expression regulation, and biological function of androgen receptor splicing variant 7 in prostate cancer","volume":"105","author":"Chen","year":"2021","journal-title":"Urol Int"},{"key":"B21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12964-022-00925-0","article-title":"Androgen receptor variant-7 regulation by tenascin-c induced src activation","volume":"20","author":"Thomas","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clgc.2019.09.015","article-title":"Androgen receptor splice variant, AR-V7, as a biomarker of resistance to androgen axis-targeted therapies in advanced prostate cancer","volume":"18","author":"Zhang","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.eururo.2016.03.049","article-title":"Analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice variant-7 protein expression in metastatic castration-resistant prostate cancer","volume":"70","author":"Welti","year":"2016","journal-title":"Eur Urol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027970","article-title":"Androgen receptor variants occur frequently in castration resistant prostate cancer metastases","volume":"6","author":"Zhang","year":"2011","journal-title":"PloS One"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0237","article-title":"In situ hybridization for androgen receptor splice variant AR-V7 as a prognostic biomarker for metastatic castration-sensitive prostate cancer","volume":"23","author":"Saylor","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PloS Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-3-25","article-title":"The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews","volume":"3","author":"Whiting","year":"2003","journal-title":"BMC Med Res Methodol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.36644","article-title":"Risk of subsequent stroke among patients receiving outpatient vs inpatient care for transient ischemic attack: A systematic review and meta-analysis","volume":"5","author":"Shahjouei","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0253379","article-title":"Effect of prebiotics on growth and health of dairy calves: A protocol for a systematic review and meta-analysis","volume":"16","author":"Lopes","year":"2021","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","article-title":"Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer","volume":"69","author":"Hu","year":"2009","journal-title":"Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/srep07654","article-title":"Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer","volume":"5","author":"Qu","year":"2015","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019059","article-title":"Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival","volume":"6","author":"Hornberg","year":"2011","journal-title":"PloS One"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.08.009","article-title":"Novel junction-specific and quantifiable In situ detection of AR-V7 and its clinical correlates in metastatic castration-resistant prostate cancer","volume":"73","author":"Zhu","year":"2018","journal-title":"Eur Urol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"18016","DOI":"10.1038\/s41598-022-22854-1","article-title":"Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer","volume":"12","author":"Ashizawa","year":"2022","journal-title":"Sci Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100915","article-title":"Identification of AR-V7 downstream genes commonly targeted by AR\/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer","volume":"14","author":"Sugiura","year":"2021","journal-title":"Transl Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.05.008","article-title":"Clonal evolution and epithelial plasticity in the emergence of AR-independent prostate carcinoma","volume":"5","author":"Laudato","year":"2019","journal-title":"Trends Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0594","article-title":"Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance","volume":"68","author":"Dehm","year":"2008","journal-title":"Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2021.03.021","article-title":"Assessment of total, PTEN(-), and AR-V7(+) circulating tumor cell count by flow cytometry in patients with metastatic castration-resistant prostate cancer receiving enzalutamide","volume":"19","author":"Di Lorenzo","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.07.024","article-title":"AR-V7 in peripheral whole blood of patients with castration-resistant prostate cancer: Association with treatment-specific outcome under abiraterone and enzalutamide","volume":"72","author":"Seitz","year":"2017","journal-title":"Eur Urol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.06.094","article-title":"AR-V7 transcripts in whole blood RNA of patients with metastatic castration resistant prostate cancer correlate with response to abiraterone acetate","volume":"197","author":"Todenhofer","year":"2017","journal-title":"J Urol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nrurol.2016.113","article-title":"Prostate cancer: AR-V7 status in CTCs is a treatment-specific biomarker","volume":"13","author":"Stone","year":"2016","journal-title":"Nat Rev Urol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1341","article-title":"Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer","volume":"1","author":"Antonarakis","year":"2015","journal-title":"JAMA Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1828","article-title":"Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer","volume":"2","author":"Scher","year":"2016","journal-title":"JAMA Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.3390\/cancers14184441","article-title":"Androgen receptor splice variants contribute to the upregulation of DNA repair in prostate cancer","volume":"14","author":"Tolkach","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2223-4683.2013.09.08","article-title":"Decoding the androgen receptor splice variants","volume":"2","author":"Lu","year":"2013","journal-title":"Transl Androl Urol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-020-0217-3","article-title":"Androgen receptor variant-driven prostate cancer II: Advances in laboratory investigations","volume":"23","author":"Lu","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0172-0","article-title":"Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases","volume":"119","author":"Kallio","year":"2018","journal-title":"Br J Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01244-6","article-title":"Transcriptional mediators of treatment resistance in lethal prostate cancer","volume":"27","author":"He","year":"2021","journal-title":"Nat Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.eururo.2017.01.011","article-title":"Comprehensive profiling of the androgen receptor in liquid biopsies from castration-resistant prostate cancer reveals novel intra-AR structural variation and splice variant expression patterns","volume":"72","author":"De Laere","year":"2017","journal-title":"Eur Urol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.01.007","article-title":"Expression of androgen receptor splice variant 7 or 9 in whole blood does not predict response to androgen-axis-targeting agents in metastatic castration-resistant prostate cancer","volume":"73","author":"To","year":"2018","journal-title":"Eur Urol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.01.037","article-title":"Androgen receptor splice variant 7 predicts shorter response in patients with metastatic hormone-sensitive prostate cancer receiving androgen deprivation therapy","volume":"79","author":"Li","year":"2021","journal-title":"Eur Urol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1172\/JCI122819","article-title":"Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer","volume":"129","author":"Sharp","year":"2019","journal-title":"J Clin Invest"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/modpathol.2017.74","article-title":"Androgen-receptor splice variant-7-positive prostate cancer: A novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients","volume":"31","author":"Li","year":"2018","journal-title":"Mod Pathol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1863","article-title":"Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer","volume":"20","author":"Yu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"161.e19","DOI":"10.1016\/j.urolonc.2017.11.001","article-title":"Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy","volume":"36","author":"Chen","year":"2018","journal-title":"Urol Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3892","article-title":"Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer","volume":"72","author":"Hu","year":"2012","journal-title":"Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1053111\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T19:57:10Z","timestamp":1676404630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1053111\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":60,"alternative-id":["10.3389\/fonc.2023.1053111"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1053111","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2023,2,14]]},"article-number":"1053111"}}